Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07159061 · ClinicalTrials.gov registry record · NA
Neurofeedback to Treat Depression - 2
A NA study of Major Depressive Disorder (MDD), sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07159061: Recruiting NA study of Major Depressive Disorder (MDD), sponsored by University of Pennsylvania.
NCT07159061 is a NA study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 80 participants, below the 155-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07159061, a NA study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD. This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.
Primary Outcome
Clinician administered scale to assess the severity of depression. MADRS scores will be compare the effect of real-time neurofeedback vs sham neurofeedback on depression outcome in patients with MDD. A MADRS score of 16 or higher is needed in order to be eligible to be enrolled in the study. The higher the MADRS score, the more depressed the individual will be. A lower MADRS score indicates that the individual's depressive symptoms have improved. A higher MADRS score indicates that the individua
Conditions Studied
Interventions
- BEHAVIORAL Active Closed Loop Real Time fMRI Neurofeedback
- BEHAVIORAL Sham Closed Loop Real Time fMRI Neurofeedback
Study Locations (1)
Pennsylvania
- Center for Neuromodulation in Depression and Stress - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2028-12-01 |
| Phase | NA |
What NCT07159061 shows while recruiting
NCT07159061 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 155-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Active Closed Loop Real Time fMRI Neurofeedback is the first listed.
NCT07159061 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07159061 about?
NCT07159061 is a clinical study titled "Neurofeedback to Treat Depression - 2". This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD. This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamical...
What is the current status of trial NCT07159061?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-11-21. Estimated completion is 2028-12-01.
What conditions does trial NCT07159061 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT07159061?
The interventions under investigation include: Active Closed Loop Real Time fMRI Neurofeedback (BEHAVIORAL), Sham Closed Loop Real Time fMRI Neurofeedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT07159061?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07159061 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07159061's enrollment target sits among peer trials
80 12th of 22 higher than 11 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk
RECRUITING · NA
-
Home-Based tDCS Treatment Of Major Depressive Disorder
RECRUITING · NA
-
Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
RECRUITING · NA
-
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
RECRUITING · NA
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI